Icu Medical Inc/de (ICUI): Robert S Swinney , director of Icu Medical Inc/de sold 1,875 shares on May 9, 2016. The Insider selling transaction was reported by the company on May 9, 2016 to the Securities and Exchange Commission. The shares were sold at $101.40 per share for a total value of $190,125.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 15, 2016, Joseph R Saucedo (director) sold 1,875 shares at $103.22 per share price.On Apr 11, 2016, Robert S Swinney (director) sold 1,875 shares at $101.35 per share price.Also, On Mar 21, 2016, Steven Riggs (VP Operations) sold 20,000 shares at $100.00 per share price.On Feb 5, 2016, Scott E Lamb (Secretary, Treasurer,) sold 974 shares at $105.00 per share price.
ICU Medical Incorporated: On Friday, May 6, 2016 heightened volatility was witnessed in ICU Medical Incorporated which led to swings in the share price. The shares opened for trading at $101.1 and hit $102.11 on the upside , eventually ending the session at $101.86, with a gain of 0.20% or 0.2 points. The heightened volatility saw the trading volume jump to 1,38,060 shares. The 52-week high of the share price is $124.69 and the company has a market cap of $1,642 M . The 52-week low of the share price is at $85.56.
Company has been under the radar of several Street Analysts.ICU Medical Incorporated is Initiated by Gabelli & Co to Buy and the brokerage firm has set the Price Target at $128. The Rating was issued on Mar 11, 2016.
ICU Medical Inc. is engaged in the development manufacturing and sales of medical devices used in infusion therapy oncology and critical care applications. The Companys product line includes needlefree connection devices custom infusion sets closed system transfer devices (CSTD) for the handling of hazardous drugs advanced sensor catheters needlefree closed blood sampling systems disposable pressure transducer systems and innovative hemodynamic monitoring systems. The Companys products are used in acute care hospitals and ambulatory clinics in more than 60 countries worldwide. Its products are categorized into three market segments: Infusion Therapy Critical Care and Oncology. Its primary products include MicroClave and MicroClave Clear Anti-Microbial MicroClave Tego needlefree hemodialysis connector Transpac disposable pressure transducers Pulmonary artery thermodilution catheters ChemoLock CSTD and components and Diana hazardous drug compounding system among others.